Based on the National Tumor Institute.

Food and Medication Administration . We are also advancing the development of ENMD-2076 as we finalize plans for an advanced late-stage clinical trial in fibrolamellar carcinoma patients, following the recent receipt of IND allowance by the FDA. We are growing our ongoing trials in triple-negative breasts cancer also, soft tissue sarcoma and ovarian very clear cell carcinoma into China as we execute on our cost-effective drug advancement strategy. Overall, individuals using rVIII-SingleChain to prevent bleeding were well controlled with 2-3 infusions per week and developed no inhibitors. Patients using rVIII-SingleChain to prevent bleeding had low annualized bleeding prices , and an annualized spontaneous bleeding price of 0.00. RVIII-SingleChain acquired improved pharmacokinetic parameters weighed against octocog alfa, the comparator.

Other entries from category "endocrinology":

Random entries